These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 16151336

  • 1. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.
    Cohen S, Shoup A, Weisman MH, Harris J.
    Otol Neurotol; 2005 Sep; 26(5):903-7. PubMed ID: 16151336
    [Abstract] [Full Text] [Related]

  • 2. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.
    Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU.
    Arthritis Rheum; 2005 Jun 15; 53(3):337-42. PubMed ID: 15934127
    [Abstract] [Full Text] [Related]

  • 3. Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss.
    Street I, Jobanputra P, Proops DW.
    J Laryngol Otol; 2006 Dec 15; 120(12):1064-6. PubMed ID: 17040588
    [Abstract] [Full Text] [Related]

  • 4. Serial audiometry in a clinical trial of AIED treatment.
    Niparko JK, Wang NY, Rauch SD, Russell GB, Espeland MA, Pierce JJ, Bowditch S, Masuda A, Gulya AJ, Gantz BJ, Hughes GB, Brookhouser PE, Hannley MT, Telian SA, Harris JP, AIED Study Group.
    Otol Neurotol; 2005 Sep 15; 26(5):908-17. PubMed ID: 16151337
    [Abstract] [Full Text] [Related]

  • 5. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.
    Lobo D, Trinidad A, García-Berrocal JR, Verdaguer JM, Ramírez-Camacho R.
    Eur Arch Otorhinolaryngol; 2006 Jul 15; 263(7):622-6. PubMed ID: 16547758
    [Abstract] [Full Text] [Related]

  • 6. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
    Van Wijk F, Staecker H, Keithley E, Lefebvre PP.
    Audiol Neurootol; 2006 Jul 15; 11(6):357-65. PubMed ID: 16988499
    [Abstract] [Full Text] [Related]

  • 7. Autoimmune inner ear disease preliminary case report: audiometric findings following steroid treatments.
    Harris DA, Mikulec AA, Carls SL.
    Am J Audiol; 2013 Jun 15; 22(1):120-4. PubMed ID: 23800807
    [Abstract] [Full Text] [Related]

  • 8. Immune-mediated inner ear disease: 10-year experience.
    Broughton SS, Meyerhoff WE, Cohen SB.
    Semin Arthritis Rheum; 2004 Oct 15; 34(2):544-8. PubMed ID: 15505770
    [Abstract] [Full Text] [Related]

  • 9. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.
    Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE.
    JAMA; 2003 Oct 08; 290(14):1875-83. PubMed ID: 14532316
    [Abstract] [Full Text] [Related]

  • 10. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR.
    Arthritis Rheum; 2004 Jul 08; 50(7):2240-5. PubMed ID: 15248223
    [Abstract] [Full Text] [Related]

  • 11. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
    Rahman MU, Poe DS, Choi HK.
    Otol Neurotol; 2001 Sep 08; 22(5):619-24. PubMed ID: 11568668
    [Abstract] [Full Text] [Related]

  • 12. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease.
    Vambutas A, Lesser M, Mullooly V, Pathak S, Zahtz G, Rosen L, Goldofsky E.
    J Clin Invest; 2014 Sep 08; 124(9):4115-22. PubMed ID: 25133431
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppressive therapy for autoimmune inner ear disease.
    Buniel MC, Geelan-Hansen K, Weber PC, Tuohy VK.
    Immunotherapy; 2009 May 08; 1(3):425-34. PubMed ID: 19885385
    [Abstract] [Full Text] [Related]

  • 14. Sex differences in autoimmune inner ear disease treatment and audiological outcomes.
    Maxwell PJ, Ranjbar PA, Winkler D, Kuzy J, McGovern B, Sataloff RT.
    Am J Otolaryngol; 2023 May 08; 44(4):103875. PubMed ID: 37058909
    [Abstract] [Full Text] [Related]

  • 15. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun 08; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 16. Autoimmune inner ear disease.
    Ruckenstein MJ.
    Curr Opin Otolaryngol Head Neck Surg; 2004 Oct 08; 12(5):426-30. PubMed ID: 15377956
    [Abstract] [Full Text] [Related]

  • 17. Pediatric fluctuating sensorineural hearing loss: problems in medical management.
    Dinces EA, Yang S, Balogun AO.
    Laryngoscope; 2001 Jan 08; 111(1):21-5. PubMed ID: 11192894
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun 08; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 19. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb 08; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 20. Demystifying autoimmune inner ear disease.
    Das S, Bakshi SS, Seepana R.
    Eur Arch Otorhinolaryngol; 2019 Dec 08; 276(12):3267-3274. PubMed ID: 31605190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.